Merus B.V., a Utrecht, The Netherlands-based biopharmaceutical company focusing on innovative human antibody therapeutics, raised an additional €31m (US$42m) in Series B financing.
This brought the total amount raised by the company in the Series B round to €47.6m (US$65m).
Bakers included new investor Johnson & Johnson Development Corporation (JJDC) and existing investors Novartis Venture Fund, Pfizer Venture Investments, Bay City Capital, LSP (Life Sciences Partners), and Aglaia Oncology Fund. A representative of JJDC will join Merus’ Board of Directors.
The company intends to use the new funds to broaden its portfolio of pre-clinical programs for the treatment of cancer patients and to bring its lead programs into phase I clinical testing.
Led by Ton Logtenberg, Chief Executive Officer, Merus has two lead programs in development:
– MCLA-128 for the treatment of solid tumors and
– MCLA-117 for the treatment of hematological malignancies.
The company is also developing a broad pipeline of preclinical programs that are available for partnering.
FinSMEs
03/10/2013
Related News
29/01/2010: The Netherlands, Merus Closes €21.7M Series B Financing